Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2019 to Sep 2024
Affymetrix Inc. (Nasdaq:AFFX) announced today that a
beta version of its next-generation instrument control software is now
available for download on the Affymetrix website. Affymetrix
GeneChip(R) Command Console(TM) (AGCC) software will replace the
GeneChip Operating Software (GCOS) and will support all
cartridge-based GeneChip arrays with a file-based system designed for
easy data sharing, a streamlined workflow, and ease of use.
AGCC, scheduled to launch commercially in early 2007, will offer
features for sample and array registration, data management, fluidics
and scanning instrument control, as well as automatic and manual image
gridding. AGCC will also produce Probe Cell intensity data (.CEL file
generation).
"Affymetrix developed the GeneChip Command Console software in
direct response to customer needs and feedback," said Greg Fisher,
senior product manager of informatics at Affymetrix. "With a
streamlined and flexible workflow that will scale with our customers'
current and future needs, Command Console software works the way our
users want. Customers will soon see the benefits of this effort as we
introduce the next-generation instrument control software for
GeneChip-brand arrays."
To read the Affymetrix UserForum interview with Greg Fisher,
please visit:
http://www.affymetrix.com/userForum/news/newProducts/GC_CommandControl
.uf (Due to its length, this URL may need to be copied/pasted into
your Internet browser's address field. Remove the extra space if one
exists.)
The new software also offers integrated data management with
extensive search capabilities, desktop and Web interface versions,
integrated instrument control, as well as easy customization and
integration with in-house and third-party software tools. Affymetrix
will continue to support GCOS into 2008.
To download the beta version of Command Console software or to
read more about it, please visit:
http://www.affymetrix.com/products/software/specific/command_console_s
oftware.affx (Due to its length, this URL may need to be copied/pasted
into your Internet browser's address field. Remove the extra space if
one exists.)
About Affymetrix
Affymetrix scientists invented the world's first high-density
microarray in 1989 and began selling the first commercial microarray
in 1994. Since then, Affymetrix GeneChip(R) technology has become the
industry standard in molecular biology research. Affymetrix technology
is used by the world's top pharmaceutical, diagnostic and
biotechnology companies as well as leading academic, government and
not-for-profit research institutes. More than 1,400 systems have been
installed around the world and nearly 4,000 peer-reviewed papers have
been published using the technology. Affymetrix' patented
photolithographic manufacturing process provides the most information
capacity available today on an array, enabling researchers to use a
whole-genome approach to analyzing the relationship between genetics
and health. Affymetrix is headquartered in Santa Clara, Calif., with
manufacturing facilities in Sacramento, Calif., and Bedford, Mass. The
company maintains important sales and marketing operations in Europe
and Asia and has about 1,100 employees worldwide. For more information
about Affymetrix, please visit the company's website at
www.affymetrix.com.
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of the
Securities Exchange Act as amended, including statements regarding
Affymetrix' "expectations," "beliefs," "hopes," "intentions,"
"strategies," or the like. Such statements are subject to risks and
uncertainties that could cause actual results to differ materially for
Affymetrix from those projected, including, but not limited to: risks
and uncertainties associated with the beta launch of the Affymetrix
GeneChip(R) Command Console discussed in this press release; risks of
the Company's ability to achieve and sustain higher levels of revenue,
higher gross margins, reduced operating expenses; uncertainties
relating to technological approaches, manufacturing, product
development; personnel retention; uncertainties related to cost and
pricing of Affymetrix products; dependence on collaborative partners;
uncertainties relating to sole source suppliers; uncertainties
relating to FDA and other regulatory approvals; competition; risks
relating to intellectual property of others and the uncertainties of
patent protection and litigation. These and other risk factors are
discussed in Affymetrix' Form 10-K for the year ended December 31,
2005, and other SEC reports, including its Quarterly Reports on Form
10-Q for subsequent quarterly periods. Affymetrix expressly disclaims
any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in Affymetrix' expectations with regard thereto or
any change in events, conditions or circumstances on which any such
statements are based.
NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered
trademarks owned or used by Affymetrix Inc.